Bionomics Ltd (BNOX)

[jedijazz]

$BNOX $1.90 +6.74% HOD $1.93

[jedijazz]

Good morning $BNOX

[Cameo Brien]

https://marketwirenews.com/articles/bionomics-shares-soar-65-since-august-ahead-of-comme-mwn4754.html

[Ryguy008]

Let's cap the week off strong today and tomorrow!

$BNOX

[Cameo Brien]

Over $2

[mick]

IHUB DEAL
Can this be true
worth big bucks
how real is this
https://investorshub.advfn.com/?imd=1012
https://investorshub.advfn.com/iHub-Membership-Drive-2023-42392
IHUB DRIVE

[Golden Cross]

Looks thin to 3

[subslover]

Happy to see you here mick!

[mick]

low ss J $BNOX

[jedijazz]

$BNOX Great day here! $1.84 +10.18% HOD $1.87

[subslover]

Ditto on your $5.00 target jedijazz :))

[jedijazz]

$BNOX Bionomics (BNOX) Up on Positive Updates on PTSD & SAD Candidate https://www.zacks.com/stock/news/2140477/bionomics-bnox-up-on-positive-updates-on-ptsd-sad-candidate $JNJ $TLRY $AMD $AAPL $TGT

[jedijazz]

$BNOX is confident that the results from the phaseIIPREVAIL study will support the progression to phaseIII.

https://finance.yahoo.com/news/bionomics-bnox-positive-updates-ptsd-155000851.html

[jedijazz]

$BNOX opens $1.68 Thin to $1.70+

[jedijazz]

Bionomics Limited (NASDAQ: $BNOX) Short Squeeze 2023-08-30 https://t.co/x68azWU9G8

[jedijazz]

$BNOX Bionomics has a CNS focused pipeline led by its programs in Social Anxiety Disorder (“SAD”) and Post-Traumatic Stress Disorder (“PTSD”), both of which received the U.S Food and Drug Administration (FDA) Fast Track Designation. https://www.bionomics.com.au/pipeline/

[jedijazz]

$BNOX - #FDA granted Bionomics Ltd NASDAQ a Fast Track designation to BNC210 for treatment of patients with PTSD and SAD. The designation provides the company with additional market exclusivity and expedited regulatory paths. https://finance.yahoo.com/news/bionomics-bnox-positive-updates-ptsd-155000851.html

[jedijazz]

Good morning $BNOX

[jedijazz]

$BNOW Great #Nasdaq here on its way to #FDA Approved list. #long

[jedijazz]

$BNOX looking for a strong close into the after hour session where we could move higher!

[Golden Cross]

Yes, that is big time

[jedijazz]

BNOX plans to meet the FDA in mid-September to discuss the clinical requirements for advancing BNC210 into phase III development, based on data of PREVAIL study. The company is confident that the results from the phaseIIPREVAIL study will support this progression.

https://finance.yahoo.com/news/bionomics-bnox-positive-updates-ptsd-155000851.html

[jedijazz]

$BNOX low float here is what can send us much, much higher!

[jedijazz]

$BNOX Bionomics Ltd. chances are very high for a favorable outcome then we could see $5+

[subslover]

Major FDA meetings scheduled during Sept. Anything under $2.00 is taking candy from a wolf's baby lol.

[jedijazz]

$BNOX One-Month High of $2.56 #Shortsneedtocover

https://www.barchart.com/stocks/quotes/BNOX/cheat-sheet

[Golden Cross]

A lot of room to run north here

[jedijazz]

$BNOX Huge volume. On alert!

[jedijazz]

$BNOX $1.79! This Low Float Biotech Is Disrupting the Sector

Bionomics Ltd. is a clinical stage biopharmaceutical company. It engages in the development of novel drug candidates focused on the treatment of serious central nervous system disorders. The company was founded in 1996 and is headquartered in Eastwood, Australia.
@BionomicsLtd @StockifyMedia


$AAPL $TSLA $VNUE $TUP $NKLA $CTNT $LIDR $YELL $TGTX $NIO $ILUS $IDAI $BMRA

[jedijazz]

$BNOX $1.70 x $1.72 Strong open here #Shortsqueeze to $3+ possible!

[jedijazz]

$BNOX @BionomicsLtd Quarterly Activities and Cashflow Report https://finance.yahoo.com/news/quarterly-activities-cashflow-report-100000099.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

[Cameo Brien]

Ready to pop

[jedijazz]

$BNOX - Bionomics Limited (NASDAQ:BNOX) Short Squeeze 2023-08-30 | Squeeze Report News

Bionomics limited is a clinical stage biopharmaceutical company. It engages in the development of novel drug candidates focused on the treatment of serious central nervous system disorders. The company was founded in 1996 and is headquartered in Eastwood, Australia.


Over the past twenty days of trading, Bionomics Limited (NASDAQ: BNOX), from August 02, 2023 to August 29, 2023 there is a potential Short Squeeze...

View the full press: https://marketwirenews.com/articles/bionomics-limited-nasdaq-bnox-short-squeeze-2023-08--mwn-news-3971.html

[jedijazz]

$BNOX @BionomicsLtd Bionomics (BNOX) Up on Positive Updates on PTSD & SAD Candidate $ANVS https://finance.yahoo.com/news/bionomics-bnox-positive-updates-ptsd-155000851.html

[Ryguy008]

Good spot premkt

$BNOX

[jedijazz]

BNOX $1.65 -Bionomics Completes Last Patient Last Visit in the Phase 2B Attune Study for Post-Traumatic Stress Disorder
August 23, 2023 at 06:00 am

Bionomics Limited announced that the last patient last visit has been completed in its Phase 2 ATTUNE study in PTSD, and disclosed timing of the End of Phase 2 (EoPh2) meeting to review advancing BNC210 into Phase 3 program in patients with SAD. The Phase 2b ATTUNE study (NCT04951076) is a double-blind, placebo-controlled, randomized study of twice daily BNC210 as monotherapy treatment for PTSD. The primary endpoint is change in a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total symptom severity scores from baseline to week 12 compared to placebo.

Secondary endpoints include change from baseline to week 12 compared to placebo on the PTSD-checklist (PCL-5), anxiety (Hamilton Anxiety Rating Scale, HAM-A), depression (Montgomery-Asberg Depression Rating Scale, MADRS), Clinician Global Impression (CGI), Patient Global Impression (PGI), sleep (Insomnia Severity Index, ISI) and disability (Sheehan Disability Scale, SDS) scales. Approximately 200 participants have been enrolled at 27 sites in the United States and 7 sites in the United Kingdom, and topline results are anticipated by the end of September 2023. The EoPh2 meeting to discuss advancing BNC210 into Phase 3 development as an acute treatment for SAD has been scheduled for mid-September 2023.

At this meeting, Bionomics will discuss with the FDA its plans for a Phase 3 program that would support the submission of a new drug application for BNC210 for the treatment of SAD. The Company believes that the results from Phase 2 PREVAIL study support the progression of BNC210 into Phase 3 and plans to provide an update by the end of 2023 following the receipt of formal meeting minutes from the FDA.

https://www.marketscreener.com/quote/stock/BIONOMICS-LIMITED-7136133/news/Bionomics-Completes-Last-Patient-Last-Visit-in-the-Phase-2B-Attune-Study-for-Post-Traumatic-Stress-D-44678531/

[jedijazz]

Good morning $BNOX

[Cameo Brien]

Good evening

[subslover]

Thank you. Huge opportunity here!

[TheFinalCD]

GOOD CALL BUD

Message in reply to:
Nice company. Plenty of room to move back up

[subslover]

Nice company. Plenty of room to move back up to $10.00 IMHO.

[Lockman]

1.59

[Awl416]

Don’t mess with algos

[Awl416]

Woo hoo

[Awl416]

Great bounce off the open.
Thank you

[LowFloatLopes]

In at 4.60 for a day trade

[makinezmoney]

$BNOX: Now 7.50 !!!!!!!!!!!!!!!!!!!!!!!!


YEEEEEEEEEEehaaaaaaaawwwwwwwwwwwwwwwwwwwwwwwwww



HELLO !


$TMNA is next



GO $BNOX

[makinezmoney]

$BNOX: Added 10k at $3.30


Letsssssssssss get this party started righttttttttttttttttttt................... RIGHTTTTTTTTTTTTTT


GO $BNOX